ACRUX (ACR) - ASX ANNOUNCEMENT 31 JANUARY 2014 AXIRON NET SALES FOR CALENDAR YEAR 2013 Acrux (ASX: ACR) today confirmed that Eli Lilly reported Axiron net sales of US$53.9 million in its financial results for the quarter ended 31 December 2013, up from US$40.6 million for the previous quarter to 30 September 2013. Global Axiron net sales for the 2013 calendar year are shown in the following table: Q1 2013 Q2 2013 Q3 2013 Q4 2013 Total for 2013 US$37.1m US$47.1m US$40.6m US$53.9m US$178.7m In addition to royalties on these net sales, Acrux will receive a milestone payment of US$25 million in March 2014, as the worldwide net sales of Axiron in the 2013 calendar year exceeded US$100 million. As advised previously, funds that are superfluous to working capital requirements will be distributed to shareholders as dividends. We remain confident about the net sales growth prospects for calendar 2014. Contact
ACR Price at posting:
$2.35 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)